Anixa Biosciences (ANIX)
NASDAQ:ANIX
Want to see ANIX full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Intellectual Property Expansion
The expansion of Anixa's patent portfolio in China strengthens its competitive position and potential for future commercialization in a major market.
Negative Factors
Negative Cash Flows
Persistent negative cash flows challenge liquidity and sustainability, potentially limiting the company's ability to fund ongoing operations and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Intellectual Property Expansion
The expansion of Anixa's patent portfolio in China strengthens its competitive position and potential for future commercialization in a major market.
Read all positive factors
Anixa Biosciences (ANIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.28M
Dividend YieldN/A
Average Volume (3M)204.54K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue GrowthN/A
EPS Growth19.02%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,527,860
10 Day Avg. Volume193,788
30 Day Avg. Volume204,545
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)8.84
Price to Sales (P/S)0.00
P/FCF Ratio-18.69
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.33K
Enterprise Value/Ebitda-9.18
Forecast
1Y Price Target
$10.50Price Target Upside232.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anixa Biosciences Business Overview & Revenue Model
Company Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-...
How the Company Makes Money
Anixa Biosciences generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These strategic partnerships often involve joint development efforts and shared acc...
Anixa Biosciences Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 210.00K | 0.00 | 512.00K |
| Gross Profit | -19.00K | -36.00K | -37.00K | 49.00K | 0.00 | 127.00K |
| EBITDA | -11.03M | -11.70M | -12.66M | -10.96M | -13.73M | -13.08M |
| Net Income | -10.31M | -10.93M | -12.55M | -9.81M | -13.60M | -12.95M |
Balance Sheet | ||||||
| Total Assets | 15.23M | 16.08M | 21.59M | 25.52M | 30.41M | 36.26M |
| Cash, Cash Equivalents and Short-Term Investments | 14.20M | 15.17M | 19.92M | 23.84M | 29.69M | 35.73M |
| Total Debt | 193.00K | 204.00K | 232.00K | 175.00K | 221.00K | 259.00K |
| Total Liabilities | 1.39M | 2.13M | 2.70M | 2.15M | 2.21M | 1.49M |
| Stockholders Equity | 15.08M | 15.16M | 20.00M | 24.34M | 29.05M | 35.44M |
Cash Flow | ||||||
| Free Cash Flow | -6.88M | -7.17M | -7.33M | -6.21M | -6.49M | -4.94M |
| Operating Cash Flow | -6.88M | -7.17M | -7.33M | -6.21M | -6.49M | -4.94M |
| Investing Cash Flow | 3.39M | 4.87M | 4.28M | -5.60M | -10.73M | -3.92M |
| Financing Cash Flow | 3.98M | 2.28M | 3.42M | 366.00K | 452.00K | 31.57M |
Anixa Biosciences Technical Analysis
Neutral
3.16
Price Trends
2.82
Positive
3.22
Negative
3.38
Negative
Market Momentum
0.01
Negative
56.91
Neutral
89.43
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIX, the sentiment is Neutral. The current price of 3.16 is above the 20-day moving average (MA) of 2.70, above the 50-day MA of 2.82, and below the 200-day MA of 3.38, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 56.91 is Neutral, neither overbought nor oversold. The STOCH value of 89.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANIX.
Anixa Biosciences Risk Analysis
Anixa Biosciences disclosed 40 risk factors in its most recent earnings report. Anixa Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anixa Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $105.28M | -9.85 | -65.55% | ― | ― | 19.02% | |
49 Neutral | $83.18M | -90.96 | -57.20% | ― | -1.10% | -135.24% | |
47 Neutral | $511.59M | -5.82 | -30.08% | ― | ― | -33.17% | |
46 Neutral | $45.90M | -2.19 | -65.56% | ― | ― | -32.85% | |
42 Neutral | $85.27M | -7.23 | 102.92% | ― | ― | ― |
* Healthcare Sector Average
ANIX
Anixa Biosciences
3.06
0.25
8.90%
ATOS
Atossa Therapeutics
5.86
-7.34
-55.60%
CSBR
Champions Oncology
5.89
-0.13
-2.16%
OKYO
OKYO Pharma Limited Sponsored ADR
1.68
0.20
13.51%
CTNM
Contineum Therapeutics, Inc. Class A
14.15
10.18
256.42%
ACTU
Actuate Therapeutics, Inc.
2.95
-6.94
-70.17%
Anixa Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Anixa Biosciences Reports Positive Phase 1 Trial Results
Positive
Dec 12, 2025
On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer vaccine, presented at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted with Cleveland Clini...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―